BridgeBio is significantly improved the development of the novel therapy for amyloid heart disease, leveraging the compound. Initial trial data indicates potential benefits for patients affected from this serious https://biotech223244.tusblogos.com/42814883/company-progresses-cardiac-amyloidosis-treatment-using-the-drug